Nephrotoxicity cisplatin in patients from the cancerology unit at Hospital Universitario Hernando Moncaleano Perdomo de Neiva
##plugins.themes.bootstrap3.article.sidebar##
PDF (Español (España))
FLIP
HTML (Español (España))
##plugins.themes.bootstrap3.article.main##
Nephrotoxicity is a side effect to the kidney damage caused by drugs used in the treatment of cancer; this is a cause of treatment interruption and dose reduction in Chemotherapy due to impaired glomerular filtration rate(GFR).This study aimed at determining the changes in renal function in adult patients with carcinoma of the cervix, testis, ovary,lung, head and neck receiving chemotherapy at theCancer UnitofUniversityHospital Moncaleano Hernando Perdomo. It is a descriptive study, case series carried outwith 77over-18-year-oldpatients with the above mentioned pathologies, treated at the oncology unit at University-Hernando Hospital Moncaleano Perdomo Neiva, from March1, 2001 to28 February,2012. It was taken into account patients reporting measurement of serum creatinine and urine Simple before and after chemotherapy cycles. GFR was calculated using the classical equation Modification of Diet in Renal Disease MDRD and Naranjo algorithm was used to observe correlation between adverse drug reactions(ADR). Differences between measures taken before and after chemotherapy cycles were established by using a student test calculated using the Stata11.1software.GFR values showed a decrease of 9.2%, after anticancer therapies. This decrease is in relation to age, tumor type and number of chemotherapy cycles.
Downloads
##plugins.themes.bootstrap3.article.details##
Goodman and Gilman’s. The Pharmacological Basis of Therapeutics, 12th Edition The McGraw-Hill Companies, Inc. pp: 60-63.
Escobar Torres, Carlos Alberto. Identificación de los efectos tóxicos producidos por los fármacos antineoplásicos utilizados en el Centro Radioncológico del Caribe en la Ciudad de Cartagena, durante el año 2010. Maestría tesis, Universidad Nacional de Colombia.2011.
Haschke M, Vitins T, Lude S, et. al. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs: Nephrol Dial. 2010;25(2):426-33.
Uehara T, Yamate J, Torii M, et. al. Comparative Nephrotoxicity of Cisplatin and Nedaplatin: Mechanisms and Histopathological Characteristics. J Toxicol Pathol. 2011;24(2):87-94.
Fujieda M, Matsunaga A, Hayashi A, et. al. Children’s toxicology from bench to bed-Drug-induced Renal Injury: Nephrotoxicity induced by Cisplatin and Ifosfamide in Children.. Sci. Vol 34, Suppl 2, Issue: Ii. 2009. Pages: SP251-P257.
Miller R P, Tadagavadi R K, Ramesh G et. al. Mechanisms of Cisplatin Nephrotoxicity. Toxins. 2010;2490-2518; doi: 10.3390
Widemann BC, Adamson PC. Understanding and Managing Methotrexate Nephrotoxicity. The Oncologist. 2006;11:694-703.
Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30(6):570-581.
Ferreiro J, García J.L., Barceló R et. al. Quimioterapia: efectos secundarios. Gac Med Bilbao. 2003;100:69-74.
Farcas A, Bojita M. Adverse Drug Reactions in Clinical Practice: a Causality Assessment of a Case of Drug-Induced Pancreatitis, Gastrointestin Liver Dis. 2009;18(3):353-358.
Busto U, Naranjo CA, Sellers EM. A method for estimating the probability of adverse drug reactions, Br J Clin Pharmacol. 1982;13(2):223-227.
Son YM, Lee JR, Roh JY. Causality assessment of cutaneous adverse drug reactions. Ann Dermatol. 2011;23(4):432-438.
Padhy BM, Shanmugam SP, Gupta YK, Goyal A. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J ClinPharmacol. 2011;71(5):777-779.
The use of the WHO–UMC system for standardized case causality assessment. Accessed at http://www.who-umc.org/graphics/4409.pdf on February, 28th, 2009.
Hartmann JT, Kollmannsberger C, et al. Platinum Organ Toxicity and Possible Prevention in Patients with Testicular Cancer. Int. J Cancer. 1999;83, 866-869.
Launay-Vacher V, Oudard S, et al. Prevalence of Renal Insufficiency in Cancer Patients and Implications for Anticancer Drug Management. Cancer 2007;110: 1376-84.
Dash A, Galsky MD, et. al. Impact of Renal Impairment on Eligibility for Adjuvant Cisplatin-Based Chemotherapy in Patients With Urothelial Carcinoma of the Bladder. Cancer. 2006;107:506-513.
